Immune cell subset
|
∆ mmHG (per SD)
|
95% CI
|
p value
|
---|
Any antihypertensive medication use (median SBP 131 mmHG) n = 1852 repeated SBP measures
|
CD3+ γδ+
|
5.10
|
3.03
|
7.17
|
< .0001
|
CD3− CD56+ CD16+
|
2.25
|
1.06
|
3.45
|
0.0002
|
CD14++ CD16−
|
− 2.02
|
− 3.61
|
− 0.43
|
0.0127
|
CD14+ CD16+
|
1.16
|
− 0.41
|
2.74
|
0.1475
|
CD14DimCD16++
|
1.52
|
0.019
|
3.30
|
0.0472
|
No antihypertensive medication use (median SBP 119.5 mmHG) n = 1928 repeated SBP measures
|
CD3+ γδ+
|
1.33
|
0.22
|
2.45
|
0.0194
|
CD3− CD56+ CD16+
|
0.76
|
− 0.67
|
2.19
|
0.2997
|
CD14++ CD16−
|
− 0.79
|
− 2.22
|
0.63
|
0.2756
|
CD14+ CD16+
|
− 0.38
|
− 1.76
|
1.00
|
0.5912
|
CD14DimCD16++
|
1.56
|
− 0.027
|
3.15
|
0.0540
|
- Numbers refer to blood pressure readings under treatment, as each participant may contribute multiple measures and may change antihypertensive medication exposure category over follow-up. ∆ mmHG (per SD) refers to a change in the average level of SBP over 10 years of follow-up